Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 0.76 |
| ▸ | CA2 | P00918 | 13/20 | 0.76 |
| ▸ | CA9 | Q16790 | 9/20 | 0.76 |
| ▸ | CA4 | P22748 | 7/20 | 0.76 |
| ▸ | CA12 | O43570 | 3/20 | 0.76 |
| ▸ | CA3 | P07451 | 3/20 | 0.76 |
| ▸ | CA6 | P23280 | 3/20 | 0.76 |
| ▸ | CA5A | P35218 | 3/20 | 0.76 |
| ▸ | CA7 | P43166 | 3/20 | 0.76 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.76 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.76 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | CA11 | O75493 | 1/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | GLS | O94925 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10797173 | 0.86 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| SCHEMBL9885775 | 0.86 | CA1 (0.70) | CA1CA2CA9CA4CA12 | |
| SCHEMBL17320001 | 0.85 | CA1 (0.56) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18100211 | 0.82 | CA1 (0.72) | CA1CA2CA9CA4CA12 | |
| SCHEMBL11929008 | 0.82 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL13711902 | 0.82 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL3501152 | 0.82 | CA1 (0.69) | CA1CA2CA9CA4CA12 | |
| SCHEMBL6448329 | 0.81 | CA1 (0.59) | CA1CA2CA9CA4CA12 | |
| SCHEMBL6448327 | 0.81 | CA1 (0.59) | CA1CA2CA9CA4CA12 | |
| SCHEMBL18656466 | 0.81 | CA1 (0.68) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2027081-B1 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2046714-B1 | Cyclopentane derivatives as antiglaucoma agents | ALLERGAN INC (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. (US) | 2015-10-01 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| EP-2019820-B1 | THERAPEUTIC PYRROLIDINE COMPOUNDS | ALLERGAN INC (US) | 2012-11-21 | — | — | EP | disclosed |
| EP-2114875-B1 | SUBSTITUTED ARYLCYLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| US-8039496-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| WO-2007140197-A1 | THERAPEUTIC PYRROLIDINE COMPOUNDS | ALLERGAN, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007140136-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC | 2007-11-22 | — | — | US | disclosed |
| WO-2007134085-A2 | ISOTHIAZOLIDINES USEFUL IN THE TREATMENT OF OCULAR HYPERTENSIVE CONDITIONS | ALLERGAN, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007131012-A1 | 12-ARYL OR HETEROARYL PROSTAGLANDIN ANALOGS | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130902-A2 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130890-A2 | CYCLOPENTANE-DERIVATIVES AND THEIR USE AS OCULAR HYPOTENSIVE AGENTS | ALLERGAN, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ALLERGAN, INC. | 2007-11-08 | — | — | US | disclosed |
| WO-2007115020-A2 | THERAPEUTIC PROSTAGLANDIN COMPOUNDS FOR THE TREATMENT OF GLAUCOMA | ALLERGAN, INC. (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259836-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | PTGIS, PTGIR, CYP11B2 | CA1 1225/4885CA2 125/4885CA9 720/4885 |
| US-20150274658-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | CA1 3777/4885CA2 3810/4885CA9 1857/4885 |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | CA1 4344/4885CA2 3900/4885CA9 3681/4885 |
| US-20070259947-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, MMP8 | CA1 3439/4885CA2 2527/4885CA9 2024/4885 |
| US-20070270387-A1 | THERAPEUTIC CYCLOPENTANE DERIVATIVES | ABCB1, CYP11B2, SLC10A1 | CA1 357/4885CA2 97/4885CA9 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.